GlassScriptPhysician profile
Ashley N Smith
NPI 1104196005
$1,376.28
in general payments reported to CMS, 2019-2025
24 companies · $504 in 2025
The $504 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $83.32 · 2021: $97.16 · 2022: $140 · 2023: $75.54 · 2024: $255 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $297.10 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $112.01 | 2019 | |
| Aspira Women'S Health INC | $107.92 | 2021-2024 | Ova1 |
| Dysis Medical, INC. | $83.32 | 2020 | |
| Abbvie INC. | $78.81 | 2019-2025 | Lo Loestrin Fe |
| Abbott Laboratories | $74.84 | 2022 | |
| Millicent US INC | $62.09 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Bayer Healthcare Pharmaceuticals INC. | $60.23 | 2024 | |
| Shield Therapeutics INC | $49.50 | 2025 | |
| Mayne Pharma Commercial LLC | $47.62 | 2025 | |
| Hologic Sales and Service, LLC | $47.34 | 2024-2025 | Aptima |
| Biosense Webster, INC. | $46.62 | 2022 | |
| Sumitomo Pharma America, INC. | $44.97 | 2023-2024 | Myfembree |
| Coopersurgical, INC. | $39.52 | 2019 | |
| Supernus Pharmaceuticals, INC. | $34.22 | 2025 | Qelbree |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $32.80 | 2023 | Nexplanon |
| Astellas Pharma US INC | $26.41 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $25.22 | 2025 | Gardasil 9 |
| Evofem Biosciences, INC. | $22.16 | 2021 | |
| Lupin INC. | $18.57 | 2019 | |
| Amag Pharmaceuticals, INC. | $17.89 | 2019 | |
| Seqirus USA INC | $17.01 | 2024 | Flucelvax, Fluad |
| Pfizer INC. | $16.21 | 2025 | |
| Mission Pharmacal Company | $13.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.